GeneDx Holdings Corp. (NASDAQ:WGS) reported mixed results for the fourth quarter, with earnings falling short of expectations even as revenue came in slightly ahead of analyst forecasts.
Shares slipped 0.07% in pre-market trading following the release.
The rare disease diagnostics firm reported a quarterly loss of $0.61 per share, well below the analyst consensus, which had projected earnings of $0.09 per share.
Quarterly revenue totaled $121.0 million, modestly exceeding the consensus estimate of $120.55 million and reflecting year-over-year growth of 27%, or 37% when excluding a one-time benefit recorded in 2024. This compares with revenue of $95.3 million in the same quarter a year earlier.
Revenue from GeneDx’s core exome and genome testing business rose 32% year over year to $104.0 million, while testing volume increased 34% to 27,761 tests.
Adjusted gross margin improved to 71%, compared with 70% in the prior-year period. However, adjusted net income declined to $4.4 million from $17.5 million reported in the fourth quarter of 2024.
“The unmet need for early, accurate genomic diagnosis is enormous, and families are waiting far too long for answers,” said Katherine Stueland, President and CEO of GeneDx. “Our team is executing at the highest level, our platform continues to scale, and GeneDx null gives us a compounding data advantage that strengthens with every test we run.”
For full-year 2026, GeneDx reaffirmed revenue guidance of $540 million to $555 million, with a midpoint of $547.5 million slightly above the analyst consensus estimate of $543 million. The company expects exome and genome revenue to grow between 33% and 35%, alongside an adjusted gross margin of at least 70%.
Full-year 2025 revenue reached $427.5 million, representing 41% growth year over year, while adjusted net income rose to $41.8 million compared with $9.4 million in 2024.